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Background: Pap screening, an effective method for cervical cancer prevention, is now supported by molecular
human papillomavirus (HPV) testing. Recently commercialised preventive vaccines also provide new tools for the
primary prevention of cervical cancer. To determine appropriate prevention strategies, the Health General Direction,
Lombardy Region, funded a project that aims to characterize and monitor HPV infections and related cervical
diseases in high-risk women.
Methods/design: VALHIDATE is a 5-year multicentre open prospective cohort study. It will recruit 7000 consenting
women aged 13–65 years to provide information about the local biomolecular epidemiology of HPV infection and
cervical diseases in high-risk women recruited from nine clinical centres and one faith-based organisation. The
study will estimate the overall and type-specific prevalence of HPV infection and cervical abnormalities. It also aims
to compare standard Pap screening with biomolecular screening, and to assist in the design of targeted regional
prevention programs directed specifically at high-risk groups. Three groups of high-risk women: 1000 HIV-infected
women (aged 26–65 years), 1000 recent migrant women (aged 26–65 years) and 3000 young women (aged
13–26 years) and 1 control group: 2000 women (aged 26–45 years) attending a spontaneous screening program,
will be recruited. Sample sizes will be revised after the first year. Adult participants will undergo conventional
cervical cytology, HPV DNA screening and genotyping. Paediatric participants will undergo HPV DNA testing and
genotyping of urine samples. HPV DNA, cytological abnormalities and HPV types will be analysed according to
demographic, epidemiological, behavioural, and clinical data collected in an electronic case report form. Overall and
stratified prevalences will be estimated to analyse the associations between HPV infection and selected
characteristics. Logistic regression models will be used to estimate crude and adjusted odds ratios. Cox proportional
hazard models will be used to estimate hazard ratios over time and between groups.
Discussion/main expected results: This study will provide substantial insight into HPV infections and related
cervical diseases in high-risk groups and will help determine appropriate regional cervical cancer prevention
strategies.
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Cervical cancer screening with cervical cytology is a
proven and effective secondary prevention strategy that
can achieve a significant reduction in cervical cancer inci-
dence in the industrialized world [1-3]. However, its effi-
cacy is linked to the extent to which the target population
is reached. Therefore, cervical cancer continues to be a
major problem in the low- and medium-resourced coun-
tries of sub-Saharan Africa, South and South East Asia
and Latin America [2,4-7]. Up to 70% of the estimated an-
nual global burden of new cases and cervical cancer
deaths occur in these countries because of their lack of an
effective screening program [8]. Recently developed sec-
ondary prevention strategies show promise for scaling up
prevention services in both developing countries and the
industrialized world. These strategies are based on human
papillomavirus (HPV) testing for high-risk HPV types,
which are a necessary intermediate step for the develop-
ment of cervical cancer and its precursors. The sole use of
HPV DNA testing as a primary screening method has
proven to be effective in randomized clinical trials con-
ducted in industrialized countries as well as in simulation
models [9-14]. Because the HPV DNA test also has a
higher sensitivity and negative predictive value for grade II
or higher cervical intraepithelial neoplasia (CIN) in im-
munocompetent women than conventional or liquid-
based cytology, the extension of screening intervals to
once every 3–5 years can be considered safe [15-17]. HPV
testing is actually the recommended follow-up of abnor-
mal cytology in women older than 30 years and after CIN
treatment [18-20].
Recently commercialized cervical cancer vaccines,
moreover, provide new tools for the primary prevention
of cervical cancer with a very high rate of protection for
more than eight years when used in women previously
uninfected by the genotypes included in the vaccines
[21-30]. The association of HPV-based screening and
vaccination in the prevention of cervical cancer has been
proven in randomized clinical trials, but several ques-
tions remain about the cost-effectiveness of the vaccine
after sexual debut, the impact of non-vaccine HPV types
and the best implementation practices [29,30]. The Ital-
ian Government (Ministry of Health) initiated a free vac-
cination program for 12-year-old adolescent girls on
January 1, 2008. All Italian regions started the vaccin-
ation program during 2008 with the aim of reaching
95% vaccination coverage of the target group in 5 years
(defined in “Intesa Stato-Regioni”, December 20th,
2007). In some regions, the free vaccine was also offered
to other age groups. In Lombardy, the regional vaccin-
ation program began in September 2008 and offers free
HPV vaccination to all 12-year olds girls. An extension
to other age groups will be considered after an evalu-
ation of the local burden and type of HPV infectionamong several risk groups and an analysis of the best
overall strategy for the control of cervical cancer.
To determine appropriate strategies for cervical cancer
prevention and to optimize the allocation of resources,
the Health General Direction, Lombardy Region, funded
a project that aims to characterize and monitor HPV
infections and related cervical diseases in high-risk
women across a wide range of ages.Methods/design
VALHIDATE (eVALuation and monitoring of HPV
Infections and cervical relATEd Diseases in high-risk
women) is a multicentre open cross-sectional and pro-
spective cohort study conducted over a 5-year period
(Dec. 2010–Dec. 2015) in the Lombardy Region. It aims
to provide information about the local epidemiology of
HPV infections and related cervical diseases as well as
the distribution of HPV genotypes across ages and in
high-risk groups of women.
The study was commissioned and funded by the
Health General Direction of the Lombardy Region and
has been approved by the ethical committees of the hos-
pitals involved in the research. Approval for the storage
of residual biological samples for further analysis was
also obtained from the hospitals’ ethical committees.
The study will recruit 7000 consenting women aged
13–65 years through nine clinical centres in four general
hospitals (4 gynaecology units, 3 infectious disease units,
2 paediatric units) and one faith-based voluntary
organization that offers primary health care for migrants
lacking health insurance.
One university virology laboratory, four microbiology
laboratories and four pathology laboratories located in
the hospitals will analyse the samples collected from the
enrolled women.
The cross-sectional study was designed to estimate the
prevalence of HPV infection, cervical abnormalities and
HPV type-specific prevalence across a wide range of age
and risk groups. The prospective cohort study was
designed to compare the standard screening procedure
(Pap test) with biomolecular HPV-testing across differ-
ent age and risk groups and to assist in the design of tar-
geted regional prevention programs directed specifically
at high-risk groups.
The secondary objectives of the study are to: a) iden-
tify the geographical distributions of HPV 16 and HPV
18 variants and their association with clinical aspects; b)
identify the prevalence, distribution and incidence of po-
tential HPV 16 and HPV 18 vaccine escape mutants; c)
monitor the HPV type distribution over time for an early
identification of the type replacement phenomenon fol-
lowing the beginning of the vaccination campaign for 12-
year-old girls in the Lombardy Region (September 2008).
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Written informed consent for participation in the study
and for the conservation of the collected samples in a
bio-bank will be asked from all eligible women and will
be essential for participation in the study.
Study population
Control arm
Two thousand women aged 26–45 years will be
recruited from those attending a spontaneous Pap
screening program (SPSW).
Testing arms
One thousand HIV-infected women (HIVW) will be
recruited from those followed up for HIV infection in
three infectious disease units. One thousand recent mi-
grant women (less than 1 year) (RMW) will be recruited
mostly through a faith-based organization, and 3000
young women (aged 13–26 years) will be recruited from
those asking for a Gynaecologic (1326G) or Paediatric
consultation (1318P). Those vaccinated with anti-HPV
vaccines prior to enrolment or during the follow-up
period will not be excluded from the study. Instead, the
vaccinated participants will be considered a subgroup to
be monitored and evaluated over time.
Exclusion criteria
Those with a history of histologically proven grade II or
higher CIN requiring treatment, who were pregnant at
the time of enrolment or who were unable to provide
informed consent are excluded from the study. For parti-
cipants aged< 18 years, written informed consent will
be required from their parents or legal guardian.
Recruitment and follow-up periods
Participants will be recruited for 12 months; this will be
extended if necessary. They will be followed up for
3 years, and the study is scheduled for completion 3 years
after the last enrolment.
Baseline evaluation and follow-up
Adult participants will undergo a medical assessment
appropriate to their group (gynaecologic evaluation, and
infectious disease evaluation for HIV-infected partici-
pants), cytological screening following the Italian Guide-
lines [31] for Cervical Cancer or algorithms modified for
HIV-infected women, and HPV DNA testing. Colpos-
copy referral will be driven by cytology results. The con-
ventional Pap smears will be evaluated according to the
2001 Bethesda System by four pathology laboratories.
HPV-DNA testing will be performed by the reference
virology laboratory. HPV DNA-positive samples will be
genotyped using a commercial kit in the four microbiol-
ogy laboratories. Oncogenic risk associated with HPVtypes will be defined according to the 2011 IARC classi-
fication [32]. Samples with a positive HPV DNA test but
with genotypes not included in the InnoLipa panel will
be typed by the restriction fragments length polymorph-
ism (RFLP) technique in the reference virology labora-
tory. In this reference laboratory, HPV 16- and HPV
18-positive cervical brushes or urine samples will be fur-
ther subjected to a phylogenetic analysis to study the cir-
culation of variants belonging to different geographical
clusters (European and non-European).
An additional analysis for the characterization of HPV
16 and HPV 18 variants that could potentially elude the
immune response induced by the vaccination (escape
mutants) will be performed.
Participants with discordant results (HPV-positive/
cytology-negative) will be recalled after 12 months for re-
assessment with cytology and HPV testing.
Paediatric participants will undergo a paediatric evalu-
ation and HPV DNA testing of urine samples. The algo-
rithms for the follow-up of adult and paediatric
participants are presented in Figure 1, Figure 2, Figure 3,
and Figure 4. All data collected during the visits and
derived from cytology and biomolecular evaluations will
be recorded on a specially developed secure electronic
case report form (eCRF).
Conventional pap smears
The Pap smear sample will be obtained by using a brush
(Cytobrush Plus MedscandW Medical AB, Sweden). Cer-
vical specimens for conventional cytology will be pro-
cessed by spreading the cells onto a glass slide, fixing
cells within a few minutes, and then sending them to the
reference pathology laboratory for investigation.
Sample collection for molecular tests
The same cervical brush used for cytology will be then
immersed and rinsed in a vial filled with 20 ml of Pre-
servCytW solution (ThinPrep Pap Test, Hologic Italia
Srl), and stored at room temperature (RT) until proces-
sing. Ten millilitres of each PreservCyt solution contain-
ing cervical cells will be centrifuged at 3800 × g for
15 min at RT. After centrifugation, the pellet will be
resuspended in 1 ml of phosphate buffered saline (PBS),
transferred into a new 1.5 ml collection test tube and
stored at −20 °C until nucleic acid isolation.
First-void urine samples will be collected in sterile
containers, kept at RT and processed within 6–8 hours
of collection. At least 15 ml of each urine sample will be
centrifuged at 3800 × g for 20 min at RT. After centrifu-
gation, the opaque phase will be recovered, transferred
into a new 1.5 ml collection test tube and then centri-
fuged at 16,000 × g for 15 min at RT. The pellets
obtained will be resuspended in 700 μl of PBS and
stored at −20 °C until nucleic acid isolation.
Figure 1 Algorithm for the screening and follow-up of SPSW and RMW. SPSW: women aged 26–65 years attending a gynaecologic visit for
spontaneous screening. RMW: recently migrated women aged 26–65 years asking for medical assessment of any health problem. HPV testing:
Nucleic acid extraction from cervical samples (by NucliSENSW EasyMAG™, bioMérieux bv, France) followed by PCR amplification of a 450-base pair
fragment of ORF L1 using the degenerate primer pair ELSI-f and ELSI-r.
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Referral for colposcopy will be driven by the Pap results.
Cytology showing atypical squamous cells or worse will
be referred for colposcopy evaluation and biopsies will
be taken from suspicious areas of the cervix, according
to the standard procedures in Italy [33]. Biopsy results
will be reported as normal, CIN grade I, II, III, or as in-
vasive cancer, according to the international criteria [34].
Nucleic acid extraction and HPV DNA detection
DNA will be extracted from cervical and urine samples
using an automated system for total nucleic acid extrac-
tion (NucliSENSW EasyMAG™, bioMérieux bv, France)
according to the manufacturer’s instructions. The concen-
tration and purity of the extracted DNA will be evaluated
through a Thermo Scientific NanoDrop 2000 spectropho-
tometer (Thermo Fisher Scientific Inc., France). DNA in-
tegrity will be assessed by amplification of a 268-base pair
(bp) fragment in the ubiquitous β-globin gene using the
primer pair PCO4 (5′–CAACTTCATCCACgTTCACC–
3′) and GH20 (5′–gAAgAgCCAAggACAggTAC–3c′) [35].
HPV DNA will be detected by PCR amplification of a
450-bp segment of ORF L1 using the degenerate primer
pair ELSI-f (5′–gCNCARggHCATAAYAATgg–3′) and
ELSI-r (5′–CgNCCHAADggAAAYTgATC–3′)[36]. Anequimolar mixture of each primer will be added to the
PCR master mix to a final concentration of 30 pmol.
PCR will be performed using GoTaqW DNA Polymerase
(Promega, Madison WI, USA) according to the manu-
facturer’s instructions. The ELSI-f and ELSI-r primers
will be used with the following amplification reaction
conditions: 5 min denaturation at 94 °C followed by 40
cycles of amplification. Each cycle will consist of a de-
naturation step at 94 °C for 30 sec, an annealing step at
55 °C for 30 sec and an elongation step at 72 °C for
30 sec. The last cycle will be followed by a 7 min elong-
ation step at 72 °C. Each PCR run will include positive
controls (DNA extracted from HPV 16-positive cells,
Caski) and negative (water) control samples. The ampli-
fication products will be revealed using an electrophor-
esis analysis of 2% agarose gels containing ethidium
bromide. Amplified product bands will be compared
with molecular weight standards (DNA Molecular
Weight, Marker 100, Sigma, St. Louis, MO).
HPV genotyping
The 450-bp fragments will be genotyped using INNO-LiPA
HPV Genotyping Extra (Innogenetics N.V., Belgium), a
line probe assay based on the principle of reverse
hybridization. Part of the L1 region of the HPV
Figure 2 Algorithm for the screening and follow-up of HIVW. HIVW: HIV-infected women aged 26–65 years. HPV testing: Nucleic acid
extraction from cervical samples (by NucliSENSW EasyMAG™, bioMérieux bv, France) followed by PCR amplification of a 450-base pair fragment of
ORF L1 using the degenerate primer pair ELSI-f and ELSI-r.
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resulting biotinylated amplicons will be subjected to
denaturation and hybridization with sequence-specific
DNA probes for the identification of 28 different HPV
genotypes: 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 43, 44,
45, 51, 52, 53, 54, 56, 58, 59, 66, 68, 69, 70, 71, 73, 74,
and 82. To establish the genotype/s present in the
sample, the line patterns will be compared with the in-
terpretation chart supplied with the assay.
HPV X
Samples for which the obtained line pattern cannot be
assigned to any genotype pattern or that have no type-
specific lines, but at least one positive HPV control line
will be scored as HPV-positive, but untypeable (HPV X).
These samples will be referred to the reference virology
laboratory for genotype analysis by RFLP. The 450-bp
fragments obtained by the ELSI-PCR protocol will be
tested by the RFLP technique with RsaI, DdeI and HaeIII
digestion enzymes (New England Biolabs, Ipswich, MA).
Briefly, 10 μl of the amplified products will be added to
three final mixtures of 15 μl containing 1U of each en-
zyme in a specific buffer. The restriction reaction will be
performed at 37 °C for 1 hour and the enzymes will bethen inactivated at 80 °C for 20 minutes. Fragments of
different lengths will be separated on 3% agarose gel.
The pattern of fragments generated by the restriction
enzymes will allow for identification of all types in the
genus alpha of Papillomaviruses.
Phylogenetic analysis of HPV 16 and HPV 18 LCR variants
For all HPV16- and HPV18-positive samples, a 730-bp
fragment of the LCR region will be amplified (HPV 16 pri-
mer sets: 16-LCRs 5′–gCTTgTgTAACTATTgTgTCA–3′
and 16-LCR-as 5′–gCTTgTgTAACTATTgTgTCA–3′;
HPV 18 primer sets: 18-LCRs 5′–ACCTgCCAAgCgTgTgC
gTg–3′ and 18-LCR-as 5′–AggTgCCTgCggTgCCAgA–3′)
[37,38]. The LCR multiple sequence alignment will be
conducted using ClustalX [39]. Sequence editing will be
carried out by means of BioEdit software [40] to com-
pare the nucleotide sequences with those of reference
strains obtained from the on-line database. Phylogenetic
trees will be constructed using the MEGA package [41],
and a bootstrap analysis [42] will be performed. HPV 16
variants will be classified into the four major phylogen-
etic branches: European (East Asia), Asian-American,
African-1 and African-2, as described by Yamada et al.
[43,44]. HPV 18 variants will be classified into two major
Figure 3 Algorithm for the screening and follow-up of 1326G. 1326G: young women aged 13–26 years asking for a gynaecologic
assessment. HPV testing: Nucleic acid extraction from cervical samples (by NucliSENSW EasyMAG™, bioMérieux bv, France) followed by PCR
amplification of a 450-base pair fragment of ORF L1 using the degenerate primer pair ELSI-f and ELSI-r.
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European (Asian-American, African-1, African-2).HPV 16 and HPV 18 escape mutants
For all HPV 16-positive samples, a 911-bp and 879-bp
fragment of the L1 gene will be amplified (1° fragment:Figure 4 Algorithm for the screening and follow-up of 1318P. 1318P:
health problem. HPV testing: Nucleic acid extraction from cervical samples
amplification of a 450-base pair fragment of ORF L1 using the degenerateL1_16_1F 5′–ATgTCTCTTTggCTgCCTAg–3′ and L1_
16_1R 5′–gCATCAgAggTAACCATAgAAC–3′; 2° frag-
ment: L1_16_2F 5’-CTATggACTTTACTACATTACAgg
CTA-3’; L1_16_2R 5′–gTTTAgCAgTTgTAgAggTAgA
TgA–3′) [45]. The overlapping of the sequences obtained
from the two amplified fragments will allow the analysis
of the L1 gene (1498-bp).young girls aged 13–18 years asking for a paediatric assessment of any
(by NucliSENSW EasyMAG™, bioMérieux bv, France) followed by PCR
primer pair ELSI-f and ELSI-r.
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fragment of the L1 gene will be amplified (1° fragment:
L1_18_1F 5′–ATggCTWTgTggCggCCTAg–3′ and
L1_18_1R 5′–gAgTCAgAggTAACAATAgAgC–3′; 2°
fragment: L1_18_2F 5′–CCAYggRCTTTAgTACATTg-
CAAgATA–3′ and L1_18_2R 5′–gTTTAgAAgACgTA-
gYggCAgATgg–3′) [45]. The overlapping of the sequences
will allow the analysis of the L1 gene (1489-bp).
Phylogenetic analysis of the sequences will be con-
ducted by the bioinformatics programs described above.
The analysis of codon-specific non-synonymous and
synonymous substitutions and the selection pressures
will be inferred by MEGA [41] and the Datamonkey fa-
cility [46].
Bio-bank
Residual biological samples collected in the PreservCyt
solution that are positive for HPV DNA and/or for cyto-
logical abnormalities will be stored at −20 °C for further
studies. Concordant HPV DNA-negative/cytology-
negative samples and residual urine samples will be
processed as follows: after centrifugation, the pellet
obtained will be stored at −20 °C and will then be avail-
able for future molecular investigations
Variables to be analysed and data security
Descriptive statistics (means ± SD or median) and fre-
quency analyses will be used to describe the whole study
sample and each cohort with regard to demographic,
epidemiological, behavioural, clinical, immunological,
and HPV vaccination status data. Data will be collected
with a specially developed e-CRF released on a web plat-
form built with PHP 5.3 and JQuery. The database
resides on MySql 5.0. The application is hosted at the
Mario Negri Institute (99% uptime guaranteed, accord-
ing to the service level agreement) with security features
according to the current laws. Anonymous data extrac-
tion will be performed at the data storage centre.
Statistical analyses
Cross-sectional study
Overall and HPV type-specific prevalence will be esti-
mated with 95% confidence intervals (CI), according to
the Poisson approximation, in the four participant
groups (three high-risk groups and control group). Lo-
gistic regression models will be used to estimates odds
ratios (OR) and their corresponding 95% CI to quantify
the associations between HPV infection and major
demographic, clinical and behavioural characteristics in
the four participant groups. All variables will be analysed
in both univariate and multivariate models to control for
major confounding factors.
Sensitivity, specificity, and positive and negative pre-
dictive values of the HPV test compared with the Paptest will be estimated overall and by group. Test per-
formance in matched pairs will be estimated with
McNemar’s tests, and proportions will be compared
using Fisher’s exact tests. Exact methods will be applied
when expected cell frequencies are less than five.
Power calculation
The sample size was calculated by taking published data
as well as economic feasibility into account to allow the
estimation of differences in the prevalence of type-
specific HPV between the high-risk and control groups.
From preliminary results obtained from the first 1300
women enrolled (717 SPSW, 290 HIVW, 160 RMW and
133 1326 G), the prevalence varied from 0.5%–2% (for
major high-risk HPV genotypes: 16, 18, 31, 51, 52, 53) in
the control group, and was 2–3 fold higher in the high-
risk groups (for HPV 16, 31, 51, 52, 53). The planed
sample of 1000 women for each high-risk group and
2000 low-risk women will be adequate to detect differ-
ences for genotypes with a prevalence of 1%–1.5% in the
control group.
Prospective study
We will analyze the incidence of new cytological abnor-
malities, progression or regression of baseline lesions,
incidence, clearance and persistence of HPV infection
for all women who had at least one follow-up visit. The
proportion of women lost to follow-up is expected to be
different in each participant group. The RMW group
may have more difficulty in returning for a follow-up
visit. Socio-demographic differences between women
who return and who are lost to follow-up will be ana-
lysed. Conversely, women in the HIV cohort, who will
be recruited from the centre they attend for HIV treat-
ment, may be more likely to attend the study follow-up
visits.
The proportions of women who we expect to be lost
to follow-up are therefore estimated at around 10%, 20%
and 60% in the HIVW, SPSW and RMW groups,
respectively.
Single and multiple infections will be defined without
considering uncharacterized HPV types (HPV X). The
Kaplan-Meier method will be used to evaluate differ-
ences in the incidence of abnormal cytology at follow-up
between women in the high-risk groups versus the con-
trol group. When appropriate, a Cox model will be used
to account for the effects of major confounding factors.
For the paediatric group, we will recruit about 250 girls
for each year of age between 13 and 18 years to estimate
the age at first HPV infection, time to clearance or per-
sistence of HPV infection, and the change after 3 years
of follow-up related to major behavioural characteristics.
All the analyses will be performed using SAS software
for Windows version 9.2 (SAS Institute Inc., Cary).
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In the last 50 years, the introduction of screening meth-
ods has substantially reduced the incidence of cervical
cancer in the industrialised world. However, inequalities
in the distribution of cervical cancer prevalence and
mortality are still present at national, regional or local
levels. In general, high-risk women are those who are
not reached for any reason by prevention and screening
programs. This study will provide substantial insight on
HPV infections and related cervical diseases, which will
enable us to define the risk of cervical cancer and its
precursor lesions in high-risk women compared with the
general population living in the Lombardy Region. In
turn, this information will assist health care providers
and policy makers to improve regional strategies and
optimize cervical cancer prevention in high-risk groups.
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